Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte-macrophage function in vitro

Transplant Immunology

Volumn 32, Issue 3, 2015, Pages 175-178

  Savikko, Johanna ^a   Rintala, Jukka M ^a   Rintala, Sini ^a   Koskinen, Petri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic allograft injury; EGFR; Erlotinib; Macrophage; Monocyte; Smooth muscle cell

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLATELET DERIVED GROWTH FACTOR B; EGFR PROTEIN, RAT; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL LINE; CELL MOTION; CHRONIC DISEASE; CORONARY BLOOD VESSEL; DRUG EFFECTS; GRAFT REJECTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR ENDOTHELIUM;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHRONIC DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; ERLOTINIB HYDROCHLORIDE; GRAFT REJECTION; HUMANS; MACROPHAGES; MONOCYTES; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84930486567     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2015.03.001     Document Type: Article

References (34)

1. Nankivell B.J., Chapman J.R. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006, 81:643-654.
2. Racusen L.C., Regele H. The pathology of chronic allograft dysfunction. Kidney Int 2010, 78(Suppl. 119):S27-S32.
3. Li C., Yang C.W. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009, 5:513-519.
4. Mitchell R.N., Libby p Vascular remodeling in transplant vasculopathy. Circ Res 2007, 100:967-978.
5. Ricardo S.D., van Goor H., Eddy A.A. Macrophage diversity in renal injury and repair. J Clin Invest 2008, 118:3522-3530.
6. Libby p Inflammation in atherosclerosis. Nature 2002, 420:868-874.
7. Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11:184-189.
8. Holbro T., Hynes N.E. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004, 44:195-217.
9. Wetzker R., Bohmer F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 2003, 4:651-657.
10. Joo C.K., Kim H.S., Park J.Y., Seomun Y., Son M.J., Kim J.T. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene 2008, 27:614-628.
11. Lautrette A.L.S., Li S., Alili R., Sunnanborg S.W., Burtin M., Lee D.C., et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005, 11:867-874.
12. Hua H., Munk S., Whiteside C.I. Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction. Am J Physiol Renal Physiol 2003, 284:F303-F312.
13. Krug A.W., Schuster C., Gassner B., Freudinger R., Mildenberger S., Troppmair J., et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem 2002, 277:45892-45897.
14. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
15. Dreux A.C., Lamb D.J., Modjtahedi H., Ferns G.A. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Arteriosclerosis 2006, 186:38-53.
16. Rintala J.M., Savikko J., Palin N., Rintala S.E., Koskinen P.K., von Willebrand E. Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury. Transplantation 2014, 98:821-827.
17. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999, 291:739-748.
18. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
19. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 2007, 25:1960-1966.
20. Myllärniemi M., Calderon L., Lemstrom K., Buchdunger E., Hayry p Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997, 11:1119-1126.
21. Nykanen A.I., Krebs R., Tikkanen J.M., Raisky O., Sihvola R., Wood J., et al. Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Transplantation 2005, 79:182-189.
22. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976, 17:565-577.
23. Savikko J., von Willebrand E. Coexpression of platelet-derived growth factors AA and BB and their receptors during monocytic differentiation. Transplant Proc 2001, 33:2307-2308.
24. Savikko J., Teppo A.-M., Taskinen E., von Willebrand E. Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: evidence for improved kidney graft outcome. Transpl Immunol 2014, 31:145-151.
25. Mazak I., Fiebeler A., Muller D.N., Park J.-K., Shagdarsuren E., Lindschau C., et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004, 109:2792-2800.
26. Min L.-J., Mogi M., Li J.-M., Iwanami J., Iwai M., Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005, 97:434-442.
27. Eguchi S., Numaguchi K., Iwasaki H., Matsumoto T., Yamakawa T., Utsonomiya H., et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 1998, 273:8890-8896.
28. Xiao F., Puddefoot J.R., Barker S., Vinson G.p Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004, 44:340-345.
29. Chan A.K., Kalmes A., Hawkins S., Daum G., Clowes A.W. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg 2003, 37:644-649.
30. Zhang H., Sunnarborg S.W., McNaughton K.K., Johns T.G., Lee D.C., Faber J.E. Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. Circ Res 2008, 102:1275-1285.
31. Stanic B., Pandey D., Fulton D.J., Miller F.J. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:2452-2460.
32. Lamb D.J., Modjtahedi H., Plant N.J., Ferns G.A.A. EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques. Atherosclerosis 2004, 176:21-26.
33. El Zein N., D'Hondt S., Sariban E. Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation. Cell. Signal 2010, 22:1437-1447.
34. Hyder A., Ehnert S., Hinz H., Nussler A.K., Fändrich F., Ungefroren H. EGF and HB-EGF enhance the proliferation of programmable cells of monocytic origin (PCMO) through activation of MEK/ERK signaling and improve differentiation of PCMO-derived hepatocyte-like cells. Cell Commun Signal 2012, 10:23-33.